Rate of Death in Fatal Diseases and Lymphocyte Reproductive Activity Normalized to Numbers of Hematopoietic Stem Cells in Blood
The goal of this study was to see how distinct reductions in lymphocytopoietic state affect the viability of patients with malignant and non-malignant pathologies, with the expectation of similar outcomes based on widely recognised immune defence theory. The changes in death rates in the adult population between the ages of + (55-62) years are opposite for malignant and non-malignant diseases, indicating a lack of protumor activity as well as the common morphogenic activity of lymphopoiesis due to its physiological weakening rather than the widely held belief that enhancing antitumor immunity is the cause. Flow cytometry was used to investigate the numbers of CD133+ and CD31+ lymphocytes, as well as those in the G2-M phases, in the total fraction of circulating lymphocytes from patients with fatal liver cirrhosis and advanced lung cancer over a long period of conventional treatment with OLT or palliative surgery followed by myelosuppressive chemotherapy. The link between specific reproductive activity, or sRA (G2-M/CD133+), and the number of committed liver a-fetoprotein-positive (AFP+) cells, as measured by exponential approximation survival curves for both diseases, was studied. Patients with abnormal sRA after OLT and LC patients with excessive sRA above a healthy level had greater death rates and shorter survival times, which coincided with significant immunosuppression produced by anti-rejection and anti-cancer therapy. Rather than cellular immunity, these findings could be explained by the morphogenesis (feeding) activity of circulating lymphocytes directed at both normal and malignant tissues. The variations in sRA could be a useful biomarker for tracking engraftment or tumour growth.
Author (S) Details
Aleksei N. Shoutko
Granov’s Federal Research Center for Radiology and Surgical Technologies, Fundamental Research Department of Saint-Petersburg, Russia.
Olga A. Gerasimova
Granov’s Federal Research Center for Radiology and Surgical Technologies, Outpatient Center for Transplantation, Hepatology, and Nephrology, Saint-Petersburg, Russia.
Viktor F. Mus
Granov’s Federal Research Center for Radiology and Surgical Technologies, Group for Lung Cancer Treatment, Saint-Petersburg, Russia.
View Book :- https://stm.bookpi.org/NVBS-V1/article/view/3171